• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen to attend the Festival of Biologics, 13-15 October 2026

May 6, 2026 | Past Events

Dr. Ettore Gilardoni will give an oral presentation entitled “Charge Variants characterization of a noncovalent dimeric fusion protein”. Follow the link for more details

Philogen to attend AACR 2026 in San Diego, 17-22 April 2026

Apr 17, 2026 | Past Events

Dr. Matilde Bocci is presenting a poster entitled “FAP-targeting Small molecule-immunostimulator conjugate bearing a novel TLR7 agonist payload induces tumor eradication and long-lasting antitumor immunity in vivo”. Dr. Abdullah Elsayed is presenting a...

Philogen to attend EADO 2026, 23-25 April 2026

Apr 17, 2026 | 2026, Events, Past Events, Scientific

Prof. Thomas Eigentler will give a talk entitled “Intralesional L19IL2/L19TNF in high-risk lacSCC patients: results from the Phase II DUNCAN Trial Exploratory Cohort”. Follow the link for more details.

Philogen is pleased to invite you to an upcoming webinar on March 30, 2026, at 15:00 GMT | 16:00 CET

Mar 30, 2026 | 2026, Events, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link or contact us at IR@philogen.com for further details.

Philogen is pleased to invite you to an upcoming webinar on November 20, 2025, at 15:00 GMT | 16:00 CET.

Nov 20, 2025 | 2025, Events, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link in the description or contact usat IR@philogen.com for further details.

Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

Oct 1, 2025 | 2025, Events, Past Events, Scientific

Dr. Emanuele Puca will give an oral presentation entitled: “Antibody-cytokine Fusions for Cancer Therapy: Late-Stage Clinical Results” Dr. Roberto de Luca will give an oral presentation entitled: “Engineering Antibody-Cytokine Fusion Proteins (Immunocytokines) for...
« Older Entries

Recent Posts

  • Philogen is pleased to invite you to an upcoming webinar on September 25, 2026, at 14:00 GMT | 15:00 CET.
  • Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2026 (Price sensitive)
  • The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2026 (Price sensitive) – Courtesy English Translation
  • Updated Phase III PIVOTAL Results for Nidlegy™ Published in the Journal of Clinical Oncology
  • Nidlegy™ Marketing Authorization Application Resubmitted to EMA

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it